References
"NIH Asks Participants in Women's Health Initiative Estrogen-Alone Study
to Stop Study Pills, Begin Follow-up Phase." National Institutes of Health.
http://www.nhlbi.nih.gov. March 2, 2004.
Accessed March 2004.
Effects of Estrogen plus Progestin on Health-Related Quality of Life. J. Hays
et al. NEJM, May 8, 2003; Vol. 348, No. 19.
FDA Approves Lower Dose of Prempro, A Combination Estrogen and Progestin Drug
for Postmenopausal Women. Press Release, March 13, 2003. http://www.fda.gov
"FDA Approves New Labels for Estrogen and Estrogen with Progestin Therapies
for Postmenopausal Women Following Review of Women's Health Initiative Data."
FDA News/Press Release. January 8, 2003. http://www.fda.gov.
Accessed March 2003.
Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Heart
and estrogen/progestin replacement study follow-up (HERS II): Part 1. Cardiovascular
outcomes during 6.8 years of hormone therapy. JAMA 2002;288:49-57.
Hulley S, Furberg C, Barrett-Connor E, et al, for the HERS Research Group.
Heart and estrogen/progestin replacement study follow-up (HERS II): Part 2.
Non-cardiovascular outcomes during 6.8 years of hormone therapy. JAMA 2002;288:58-66.
Writing Group for the Women's Health Initiative Investigators. Risks and benefits
of estrogen plus progestin in healthy postmenopausal women: principal results
from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
"Postmenopausal Hormone Therapy." National Heart, Lung and Blood
Institute. http://www.nhlbi.nih.gov.
Updated June 2003; accessed August 2003.
Lacey, James V., et al. "Menopausal Hormone Replacement Therapy and Risk
of Ovarian Cancer." JAMA 2002. Vol. 288:334-341.368-369.
American Heart Association Science Advisory. "Hormone Replacement Therapy
and Cardiovascular Disease: A Statement for Health care Professionals From the
American Heart Association." July 2000.
http://www.americanheart.org.
Cauley JA, Black DM, Barrett-Connor E, Harris F, Shields K, Applegate W, Cummings
SR. Effects of hormone replacement therapy on clinical fractures and height
loss: The Heart and Estrogen/Progestin Replacement Study (HERS). The American
Journal of Medicine. April 15, 2001. Vol 110(6), pp. 442-450.
"Disease Statistics" National Osteoporosis Foundation. Updated Feb.
2003. http://www.nof.org.
Accessed Sept. 2003.
"FDA Approves Seasonale Oral Contraceptive" FDA Talk Paper. Sept.
5, 2003. http://www.fda.gov.
Accessed Sept. 2003.
"Incidence and Mortality Rate Trends" National Cancer Institute.
Updated March 2003. http://prg.nci.nih.gov,
Accessed Sept. 2003.
Journal of the American Medical Society press release on the study: http://www.ama-assn.org
Letter from Anthony Glaser on relative risk, JAMA, Aug. 9, 2000, Vol. 284,
No. 6: http://jama.ama-assn.org.
Accessed Sept. 2003.
National Institute of Child Health and Human Development, Facts about Endometriosis,
http://156.40.88.3
"Study Shows Greater Risk of Breast Cancer with Estrogen-Progestin Therapy
Compared to Estrogen Alone" National Cancer Institute. Jan. 2000 http://rex.nci.nih.gov.
Accessed Sept. 2003.
National Institutes of Health, Facts About Oral Contraceptives, information
on the progestin1. Estrogen should be combined with a progestogen for hormone
replacement therapy: -only "mini-pill," http://www.nih.gov
"Oral Contraceptives and Cancer Risk." National Cancer Institute.
Reviewed Feb. 2003. http://cis.nci.nih.gov/fact/3_13.htm.
Accessed Sept. 2003.
"Progestin-only oral contraceptive pills" Reproductive Health Outlook.
Copyright 1997-2001. http://www.rho.org
"Rates of Dementia Increase Among Older Women on Combination Hormone Therapy"
NIH News. National Institutes of Health. http://www.nih.gov.
May 27, 2003; accessed Sept. 2003.
Schairer, Catherine, Jay Lubin, Rebecca Troisi, et al. Heightened breast cancer
risk for women on estrogen-progestin HRT: Menopausal Estrogen and Estrogen-Progestin
Replacement Therapy and Breast Cancer Risk. Journal of the American Medical
Association. Jan. 26, 2000. Vol 283, pp. 485-491.
Solvay press release on approval of Prometrium. Updated July 2003. http://www.solvaypharmaceuticals-us.com.
Accessed Sept. 2003.
Torgerson DJ, Bell-Syer SE. The Journal of the American Medical Association.
Hormone Replacement Therapy and Prevention of Nonvertebral Fractures: A Meta-analysis
of Randomized Trials. June 13, 2001. Vol 285, pp. 2891-2897, 2909-2910.
U.S. Food and Drug Administration Birth Control Guide. Updated Aug. 2002. http://www.fda.gov.
Accessed Sept. 2003.
Collins, John A. Sexuality, Reproduction and Menopause, a Supplement to Fertility
and Sterility, October 2003. How Does the WHI Study Alter the Risk-Benefit Ratio
of HT?.
Progesterone for non-contraceptive use. National Institutes of Health. April
2005. Available at: http://www.nlm.nih.gov.
Accessed: November 2005.
Ross, RK et al. Effect of hormone replacement therapy on breast cancer risk:
estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000 Feb 16;92(4):328-32.
Li, CI et al. Relationship between long durations and different regimens of
hormone therapy and risk of breast cancer. JAMA. 2003 Jun 25;289(24):3254-63.
Menopausal Hormone Replacement Therapy and Cancer Risk. The American Cancer
Society. October 2004. Available at: http://www.cancer.org.
Accessed: November 2005.
Black Box Warning Added Concerning Long-Term Use of Depo-Provera Contraceptive
Injection. [press release]. Food and Drug Administration. November 2004. Available
at: http://www.fda.gov.
Accessed November 2005.
| |
|
View References for this Health Topic
|
Create Date: 2/20/02
Date Last Updated: 3/16/06
Review Date: 2/4/06
|
|
